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Growth hormone (GH) constitutes a set of closely re-
lated protein isoforms. In clinical practice, the dis-
agreement of test results between commercially avail-
able ligand-binding assays is still an ongoing issue, and
incomplete knowledge about the particular function of
the different forms leaves an uncertainty of what should
be the appropriate measurand. Mass spectrometry is
promising to be a way forward. Not only is it capa-
ble of providing SI-traceable reference values for the
calibration of current GH-tests, but it also offers an
independent approach to highly reliable mass-selective
quantification of individual GH-isoforms. This capabil-
ity may add to reliability in doping control too. The
article points out why and how.
Measurand
Growth hormone (GH) is a heterogeneous polypeptide
consisting of a number of different isoforms and vari-
ants.1 These are closely related to one another as origi-
nating from the same gene, i.e., information about GH-
amino acid sequence stored on DNA. In reality, however,
just parts of this sequence are read when assembling
the GH while others are skipped (alternative splicing).
Typically, therefore, the different forms share much of
the parent sequence, but not all.
The sequence of the main GH-form (22 kDa-GH) is
shown in Figure 1. This form accounts for 58–82% of
the circulating GH.1 There is another one, 20 kDa-GH,
which is lacking in 15 out of the 191 amino acids of the
main form. These are marked by grey-filled circles in
the Figure. Next to 20 kDa-GH, which is estimated to
make a 3–15% fraction of GH forms,1 sequence frag-
ments consisting of amino acids 1–43 have been identi-
fied and the complementary stretch (44–191) has been
detected in blood.2
Further complicating matters, different variants may
exist of the same isoform by modification of the side
chains, typically resulting from deamidation or glyco-
sylation. Last, but unlikely to complete the list, the
hormone has been detected in dimeric or even higher
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molecular forms,1 e.g. (22kDa)2, (20kDa)2 or (22kDa-
20kDa), as protein-protein complexes, besides dimers
(22kDa)2 with the monomers linked by disulfide bonds.
Obviously, in this setting, the crucial problem con-
sists in knowing, which are the different functions in
regulation, exerted by the different forms, and which
of them is (are) correlating best with a particular clin-
ical condition or GH-related disease to be detected or
measured. Finding out about this requires the analyt-
ical technology to resolve these forms while providing
reliable quantitative results for each of them.
Mass spectrometry (MS), relying on a fundamentally
different principle of analyte-recognition enables eval-
uation of ligand-binding assays (LBAs) without being
subject to the same limitations as these. The analytical
selectivity generally inherent to MS can be deployed to
discriminate isoform-specific GH-sequence fragments.
This, in combination with the option to use isotope-
labeled internal standards, makes MS an interesting al-
ternative that can contribute to respond to the chal-
lenge stated above.
The subsequent discussion is intended to illustrate
this fact by the comparison of both kinds of approach,
ligand binding vs. mass selective.
Recognizing by epitope
Scope and bounds
For a long time, the ligand-binding assays have been
the only way to quantification of GH in biological sam-
ples. Apart from this inevitableness, ease of practical
implementation and automation, as well as effectiveness
in time and costs per analysis are assets of the method
principle. Importantly also, sensitivity requirements of
clinical tests can be satisfied by use of appropriate de-
tection techniques, as e.g. chemiluminescence. Then,
detection limits can be achieved of 0.2 ng/mL, or less3
as e.g. needed for measurement of GH-concentrations
in patients with growth hormone deficiency (GHD).
At the same time, the limited quality of GH-data
is still hampering the reliability of conclusions in di-
agnostic practice. Figure 2 exemplifies this with re-
sults reported by testing laboratories in one of the pe-
riodic studies organized by RfB DGKL, one of the Ger-
man providers of External Quality Assessment Services
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Figure 1: Parent-primary structure (amino acid sequence) of GH. With 22 kDa-GH, all 191 amino acids are present,
whereas 20 kDa-GH lacks in substretch 32–46 (grey-filled circles).
(EQAS). With both of the serum pools, A and B, the
spread of data covers a considerable portion of the range
of values typically found in the population as a whole, in
spite of the fact, that A and B represent serum of just
a single subject, each. Decision limits for diagnostic
GH-stimulation tests, for illustration, are in the range
of about 4–10 ng/mL.4
The situation very much resembles what is observed
in other countries too. Some further examples describ-
ing the impact of solely the choice of the assay-method
(laboratory) employed, on patient classification, are
provided by Wieringa et al. 5 In one of them, a factor
of 6, on average, was in-between the results of two dif-
ferent test-kits that had been used with an oral glucose
tolerance test.6
Limiting factors
A recent review5 summarizes the most likely causes for
intermethod-discrepancies, and why they continue to be
unsatisfactory in spite of improvements resulting from
standardization efforts during these last ten years.
One category of sources is the different affinity of an-
tibodies toward different forms of GH. In the past, test
kits were predominantly based on polyclonal antibodies.
These are mixtures of antibodies recognizing different
epitopes, each one, on the GH molecule. In this way,
in summa, all possible epitopes on the different GH-
forms are more or less covered. Therefore, polyclonal
antibodies may be expected to capture something like
’total-GH’ in that sample.
It is different, when monoclonal antibodies are used,
as it is the case with most of the more contemporary
assays. Uniformly, the same epitope is then recognized.
Depending on the presence of this epitope exclusively on
just one GH-form, or on many forms, the information
content will be either of the kind ’total-GH’ or ’particu-
lar GH form’. Enhanced specificity toward a particular
form can be achieved if using two-step immunometric
assays with two antibodies recognizing two different epi-
topes that are only present with that form.
All these antibodies, or antibody-mixtures, capture
different fractions out of the spectrum of isoforms
present in a given sample, according to the epitope(s)
they recognize. Using different methods is equivalent,
therefore, to allow for slightly different definitions of the
measurand. This obviously accounts for a part of the
variation of results if using different methods.
Figure 2: Results in an intercomparison of testing laborato-
ries for the measurand ’growth hormone’ (HP 4/12) in 2012.
A number of 14 different test kits had been employed by 186
participating laboratories. Each laboratory ran two samples
(serum pools A and B) under their routine conditions. Pairs
of results (one for pool A, one for B) make one dot in the
picture. Red triangle and blue circle: MS results (red: T6-
based, blue: T12-based). (Reproduced/adapted with per-
mission from https://www.dgkl-rfb.de. c© 2012 DGKL, Ref-
erenzinstitut fu¨r Bioanalytik.)
Potential cross-reactivities of antibodies constitute
another noticeable input to inter-method divergences.
Mistaking a non-GH antigen for GH, as it can happen
owing to similarity of epitopes, may result in positive
bias. However, it can equally well come to pass in-
versely. So, e.g., if in a sandwich-type assay just one of
2
Figure 3: Tryptic cleavage sites on 22 kDa-GH. Cleavage occurs after R and K, blue-filled circles. Substretches T6 and
T12, used as signature peptides with the method illustrated in Figure 4, are highlighted in red and green, resp. T6 is
present as shown, only with 22 kDa-GH, while the 20 kDa isoform is missing the amino acids within the grey box (cp.
Figure 1). T12, on the other hand, will equally result from both forms. Therefore, T6 captures GH in an isoform-specific
way, whereas T12 might be taken as measuring ’total-GH’.
the two antibodies binds to that antigen, less of GH will
be determined than what is present. One example for
such antigen is pegvisomant, which may interfere with
GH measurement if administered in therapy.7
However, pegvisomant is present only in sera of
treated patients. Growth hormone binding protein
(GHBP), which is generally present in serum samples at
varying concentration, apparently constitutes still more
of a problem. With commercial assays, GH-recovery
has been reported to be reduced by up to about 40%
as a consequence of GHBP interference.8 This may be
taken as resulting from competition between the bind-
ing protein and the antibody for the same GH-epitope.
Apart from these uncertainties, which may be as-
cribed to variably specific recognition of the analyti-
cal target, a more elementary factor contributing to in-
compatibility has been that, originally, and for a long
time, varying GH-preparations have been referred to
as primary standards for assay-calibration. These were
pituitary-tissue extracts containing the whole spectrum
of isoforms in poorly characterized amount-ratios. Ad-
ditionally aggravating it was, that measurement was
linked to International Units of biological activity (IU),
and not compatible, therefore, with the SI. This,
however has been resolved by a WHO-agreement in
2001,9 about using recombinant 22 kDa-GH (WHO-
preparation 98/574) for calibration, from then on, as
chemically well-defined pure primary standard. This,
at the same time, allows for expression of the results in
terms of the (molar) amount-of-substance, establishing
a link to the SI, thereby.
Finally, non-commutability of kit-calibrators is dis-
cussed as another cause of inaccuracy. ’Commutability’
addresses the requirement for the calibrator to behave
in the same way as if it was a natural (patient) sam-
ple, though most of the time the calibrators are pro-
cessed serum to which a known amount of GH had been
spiked. Non-commutability, is attributed to presence
of the analyte in a non-natural form in the calibrator,
matrix-effects, and lack of specificity of measurement
procedures,10 and will obviously affect the applicabil-
ity of calibration to real samples, and compromise the
SI-traceability of results.
Recognizing by mass
Targeting signature peptides
Several MS approaches have been developed thus far
for measurement of serum GH, on purposes to de-
tect illicit administration in stock-breeding and horse-
racing,11,12 next to diagnosis of GH-related diseases in
human medicine.13–15
All these methods share in common, that enzymatic
cleavage products of GH are quantified as surrogates
(signature peptides),16 in place of the protein itself.
The preference of enzymatic fragments as analytical
targets over the intact protein is characteristic for al-
most exclusively all methods presently being developed
in quantitative proteomics. This is obviously owing to
the better compatibility with reversed phase chromatog-
raphy and lower limits of detection/determination at-
tainable with peptides if compared to the larger-sized
precursor proteins. It is worth noting that, notwith-
standing, the alternative of measuring the intact pro-
tein, as an option is kept in consideration too.17,18 This
appears mainly motivated by the complementary infor-
mation, available in this way, about kind and abundance
of different molecular variants of the protein.
There are 20 tryptic cleavage points on 22 kDa-GH
(i.e., after each K or R) as shown in Figure 3. Of
the resulting 21 substretches (products of exhaustive
proteolytic cleavage), most can act as an analyte, pro-
vided that, they are specific enough in sequence, so
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as to be excluded from possibly being obtained simi-
larly from any other protein present in the sample. Ar-
sene et al. 13,14,19 for instance, chose T6 and T12 to be
quantified. Both sequences had been checked by com-
parison with the Swiss-Prot data base not to coincide
with sequence stretches that might result from any other
known human protein.
Integrating isotope-labeled standards
MS-Methods developed for clinical GH-measurement al-
most compellingly have to employ isotope-labeled ver-
sions of the analyte as internal standards, so as to
achieve the level of quantitative accuracy required. Ide-
ally, the target protein is used to this, since clos-
est mimicing the behavior of the analyte in both,
extraction and proteolysis.20,21 In the case of GH-
measurement, recombinantly engineered 22 kDa-GH
has been employed, either incorporating labeled nitro-
gen (U-15N GH),14 or labeled amino acids (K and R).15
As alternative to whole-protein labeling, isotope la-
beled peptides (corresponding to the specified enzy-
matic fragments) have been shown to be applicable as
internal standards too.13 Using labeled peptides as in-
ternal standards, of course, takes as a prerequisite that,
proteolysis will proceed to completion under the exper-
imental conditions used (see Arsene et al. 22 for a dis-
cussion).
Extracting targeted peptides
Once cleavage products have been specified, two fun-
damentally different strategies for generating and ex-
tracting them are conceivable: Promising it is, to first
isolate the protein from the matrix and only then to
enzymatically digest the analyte-enriched extract.
This rationale, referred to as ’protein level clean-
up’, is practiced with the method developments by
Bailly-Chouriberry et al. 12 and Le Breton et al.,11
who isolate GH by precipitating it from the serum
at its iso-electric point, followed by solid-phase ex-
traction, as well as by Pritchard et al.,15 who apply
two-fold solid-phase extraction at different pH-values.
Immunoaffinity-enrichment is likewise considered as an
option for clean-up at the protein level.23,24 This ap-
proach is also referred to as ’mass spectrometry based
immunoassay’ (MSIA), so as characterizing it as a hy-
brid of two philosophies pursued. However, with respect
to the present purpose, employing an antibody-based
extraction principle for GH ostensively would thwart
the intent of developing a method that is completely
independent of biases associated with analyte selection
by epitope recognition.
As opposed to these approaches, the alternative strat-
egy (peptide level clean-up) appears to be considerably
more challenging at first glance, indeed. In this case,
the signature peptides have to be recovered after diges-
tion from the serum sample as a whole, which results in
a matrix of very high complexity. However, in practice,
this has been proven to be manageable both, reliably
stable quite as much, as reproducible. An outline of the
implementation described by Arsene et al. 19 is given
in Figure 4. Data exemplifying accuracy and precision
attainable with the type of method are reproduced in
Table 1. Remarkably, this appears to be the only MS-
based method as yet, that has been proven to smoothly
be applicable to patient sera within a clinical study.19
Figure 4: Determination of GH by ID-MS using peptide
level clean-up. The serum sample containing GH is enzy-
matically digested using trypsin as protease. Enzymatic
GH-fragments, peptides T6 and T12, are quantified as surro-
gates in place of the intact protein. Along with each individ-
ual serum sample, a calibrator (serum plus a known amount
of 22 kDa-GH, here: WHO IS 98/574) is run and analyzed
using the same procedure as with the sample. Isotopically
labeled GH (here: U-15N 22 kDa-GH) is spiked as the in-
ternal standard to both serum sample and calibrator at the
beginning of the procedure. T6 and T12 given in red letters
are to indicate the isotope-labeled versions of the fragments.
(Reproduced with permission from Wagner et al.,19 Eur J
Endocrinol, 2014, accepted. c©2014 European Society of
Endocrinology)
Reversed phase chromatography (RP-LC) followed
by strong cation exchange (SCX) chromatography are
used, in this case, for extraction of GH peptides T6 and
T12 from the matrix. Smilar developments, targeting
other proteins, successfully have been using antibodies
instead, specifically developed for recognition of the sig-
nature peptides.24–26 This is more than likely to work
quite as well with GH-quantification and may even be
less time-consuming than chromatographic clean-up.
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Using chromatography, on the other hand, obviates
the need to develop a separate antibody against every
targeted peptide, making it more easy to switch to an-
other peptide, if required with a particular study.
Establishing SI-traceability
Traceability can be obtained by reference to a calibrator
consisting of (GH-stripped) blank serum, which is then
fortified with a defined amount of recombinant 22 kDa-
GH. The calibrator is run according to the same steps
and conditions as applied with the sample. The analysis
result, eventually, is obtained by relating the signal ra-
tio (peptide/isotope-labeled peptide) measured for the
sample, to the ratio obtained for the calibrator. In Fig-
ure 4, WHO IS 98/574 is specified as 22 kDa-GH ma-
terial appropriate for the purpose. However, any other
source would do quite as well, as long as it is of the
correct amino acid sequence and sufficient in purity.
Value-assignment to the calibrator stock solution is
based on amino acid analysis (AAA), i.e., complete hy-
drolysis, quantitatively releasing the individual amino
acids. These, in turn, are quantified by isotope dilution
mass spectrometry (ID-MS). In this way, the amount of
GH measured for a particular sample is traceable to the
(molar) amount-of-substance of the constituent amino
acids, which are simple molecules and readily available
as purified reference standards. See Burkitt et al. 27 for
a more detailed discussion of the concept.
Growth hormone by MS– scope and
bounds
Analytical selectivity and sensitivity
The promise of mass spectrometry consists in achiev-
ing enhanced selectivity by recognition of analyte mass,
rather than -epitope, as principle for distinction from
the background. Essentially, the data shown in Table 1
account for accurate recovery of GH and indicate the
absence of interferences. Apart from a bilateral com-
parison,15 no comprehensive interlaboratory study has
been run yet for MS-measurement of GH. However, re-
sults obtained by Cox et al. 28 in a recent study about
insulin-like growth factor 1 (IGF-1), which poses a simi-
lar analytical challenge, are promising. IGF-1 is partic-
ularly interesting by its close physiological relationship
with GH. In that study, five laboratories, using differ-
ent LC/MS-MS platforms, demonstrated comparability
within 5.6%. U-15N IGF-1 was employed as isotope la-
beled material in the example.
Selectivity and sensitivity achievable with MS is fur-
ther illustrated by the example shown in Figure 5, with
no other signals present in the ion chromatograms, but
those at the known retention times of the peptides T6
and T12. In contrast to presently prevailing percep-
tion29,30 this example of a serum-GH measurement at
1 ng/mL also suggests that, MS-techniques can be run
as sensitive, as making them competitive to contem-
porary antibody-based assays, even in concentration
ranges required with glucose-tolerance tests, where cut-
off levels have been reported of about 0.5 ng/mL.31
Recovery (%)
Spiked (ng/mL) By T6 By T12
4.63 103.5 104.1
4.58 97.2 100.4
10.19 100.5 102.9
10.25 98.9 99.0
19.51 103.9 102.5
19.32 102.0 96.8
29.39 104.0 99.3
30.31 103.1 100.4
Mean recovery (%) 101.6 100.7
CV (%) 2.5 2.4
LoQ (ng/mL) 1.7 2.7
Table 1: Recovery of 22 kDa-GH from serum by MS. (Re-
produced in adapted form with permission from Arsene
et al.,13 Anal Biochem, 2010, 401, 228–235 c©2010 Else-
vier Inc.)
Figure 5: Signals obtained from a serum sample at 1 ng/mL
GH. Tryptic peptides T6 and T12 of GH had been extracted
and were then analyzed by LC/MS-MS using the masses of
collision fragments (at m/z 531.25 and 671.35) for monitor-
ing. Instrument: Orbitrap-Elite at 60.000 mass-resolution.
Needless to elaborate that, selectivity and sensitiv-
ity are largely interrelated and many factors in sam-
ple preparation, as well as instrumental set-up, have
to be optimized so as to touch the limits of what is
technically possible. The first version13 of the pro-
tocol outlined in Figure 4 (p.4) was developed on a
triple-quadrupole MS instrument. Monitoring collision
fragments of T6 and T12, rather than unfragmented
ions, essentially contributes to selectivity, as includ-
ing a sequence-dependent parameter (fragment mass)
for further distinction from matrix components, that
might chance to have the same mass as T6 (or T12).
The result shown in Figure 5, however, was obtained
under conditions of high mass-resolution as achieved
by using an Orbitrap mass spectrometer in place of
the quadrupole instrument. This, apparently, does not
just further increase selectivity, but it also improves the
signal-to-noise ratio, and sensitivity, thus. Another op-
tion to enhance sensitivity consists in peptide conjuga-
tion to enhance amphipathicity, and ionization yield, by
5
Figure 6: Dependence of serum growth hormone (GH) assay results on binding protein (GHBP) level. Two commonly
used antibody-based assays (IMMULITE, black triangles and iSYS, red circles) are compared with mass spectrometry
(ID-MS, black squares). A GHR Fc chimera was spiked to serum so as to mimic increasing concentrations of the binding
protein. The dashed horizontal line indicates the known concentration of 22 kDa-GH. ID-MS data shown are avarages from
T6-based and T12-based GH measurement. (Reproduced from Arsene et al.,32 ArXiv e-prints, 2014, arXiv:1405.3895)
this way. So, e.g., based on selective tagging at cysteine,
the limit of quantification (LoQ) could be improved by
a factor of four in a later published variant of the pro-
tocol.14
Susceptibility to interfering proteins
Owing to the advantage of high selectivity, as pointed
out, mass spectrometric quantification of GH is not
likely to be biased in presence of whatever background
of accompanying proteins. Consequently, interference
by growth hormone binding protein (GHBP), as com-
monly observed with many ligand-binding assays, is ex-
pected to be irrelevant with MS-based measurement.
This is confirmed by the data shown in Figure 6.
Samples from a serum pool with defined concentra-
tion of GH (9 ng/mL) had been fortified with varying
amounts of binding protein, such as reflecting the clin-
ically relevant concentration range. The MS-method
accurately recovers the total amount of GH, while the
antibody-based assays report only the fraction that is
accessible to the antibodies at the equilibrium of com-
petitive binding.
Obviously, MS is highly reliable if it is about the total
amount of GH in the sample. At the same time, it
does not, of course, resolve in what aggregation state
(free, receptor-bound, dimerized, etc.) the hormone is
present. It cannot be ruled out, however, that these
fractions contribute essential information to description
of the physiological status of a patient and might evolve
as relevant measurands too.
Taking account of this, Frystyk et al. 33 used ultrafil-
tration to remove the receptor-bound GH fraction prior
to quantification of the remaining ’free GH’. A correla-
tion was found, by these authors, between total and free
GH for a given (constant) level of GHBP. This suggests
redundance between the two measurands. If so, just one
of the two would be neded for diagnostic purposes in re-
ality, provided the GHBP level be known at the same
time for that sample. Unfortunately, no MS-method,
has been reported yet for GHBP-quantification, but
could be useful in the context.
Frystyk et al. also found an inverse correlation of free-
GH and GHBP levels (for a given total amount of GH).
This is supportive of the notion that, GHBP serves to
control the levels of ’active’ GH available to the recep-
tors. The example illustrates, that there may be no
single and simple measurand sufficiently describing the
clinically relevant interaction of the different molecular
players in growth hormone signaling and metabolism.
Returning on the high-selectivity advantage by MS,
it should be mentioned that, GH-measurement by MS
might cope with presence of pegvisomant, even in high
excess, in a similar way, as it does with GHBP. This, of
course, requires signature peptides to be selected, which
are different between GH and pegvisomant.
Providing reference values
MS-measurement, as pointed out, enables acquisition
of SI-traceable values for (total) GH, which can serve
either as reference values for this measurand within
EQAS, or for calibration of LBAs.
Viability of calibration of LBAs, concedingly, is lim-
ited by the fact that, the (unknown) GHBP level is
involved in the outcome. Obviously, correct results can
be only expected, if this level is the same in the calibra-
tor as with the particular sample. This, however, is not
the case, most of the time. As a strategy to eliminate
this problem, dissociation of GHBP-antigen complexes
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under acidic conditions has been proposed to be applied
to the samples prior to the assay.34
Recently, Physikalisch-Technische Bundesanstalt
(PTB) has started to provide MS-values for intercom-
parisons as shown in Figure 2 (p.2). PTB’s capability
of SI-traceable MS-based GH-measurement has been
approved at international level by a ’Calibration and
Measurement Capability (CMC-Claim)’ registered at
the Bureau International des Poids et Mesures (BIPM)
[http://www.bipm.org/en/cipm-mra/].
Capturing isoform-specific
Up to this point, discussion of the MS method was re-
stricted by the assumption that, the 22 kDa-GH form
exclusively appears in a sample. However, the concept
of quantifying GH by signature peptides allows for sep-
arate measurement of the minor abundant GH-forms
too, which are present, in a natural sample, next to
22 kDa-GH.
T6, for instance, as it is shown in Figure 3 (p.3),
selectively captures the 22 kDa-GH form. The pep-
tide cannot result from 20 kDa-GH, as the amino acids
within the grey box would miss with this isoform (next
to further deviations). For the purpose of quantification
of the 20 kDa form, on the other hand, (20 kDa-) T4
would be one out of the possible signature peptides. (T4
refers to the fourth tryptic peptide produced from the
protein, starting enumeration from the N-terminus.)
In a similar way, numerous peptides can be specified,
which selectively measure a particular form of GH that
is of interest in a study. In most of the cases, more
than just one cleavage product is available to represent
the same GH-form. If simultaneously quantifying more
than one, the redundancy can be used to enhance reli-
ability by averaging the results. Also important to ob-
serve that, the individual results will additionally pro-
vide ’checks and balances’ as they should all be the same
within measurement uncertainty. In the case of a dis-
crepancy, particularly, if one predicted fragment should
not be detected at all, this may indicate an unexpected
structural deviation in the GH-sequence with that par-
ticular sample, altering the molecular mass of that pep-
tide. Changes like this might result from e.g. mutation
(substitution of amino acid) or side-chain modification.
Revising measurands
The option of separately monitoring different GH-
forms in high-selectivity/high-reliability mode will fore-
seeably impact progress in GH research too. Based
on MS-measurement, decisions could become possible,
where data from LBAs are leaving things ambiguous,
presently.
One example, where such progress might be antici-
pated, is about the influence of the spectrum of circu-
lating GH-isoforms on the occurrence of short stature
in children. Different studies lead to different conclu-
sions: While results by Boguszewski et al. 35 suggested
that elevated levels of non-22 kDa forms (which mainly
Figure 7: MS in definition of diagnostic cut-off levels. Re-
sults are shown for healthy (0) and GH-deficient children
(1). Signature peptides 22 kDa-T12 (a) and -T6 (b) were
quantified. Monitoring T12 is equivalent to mapping total
GH whereas T6 reflects 22 kDa-GH. (Graphical represen-
tation of data contributed to a recent publication: Wagner
et al. 19 Eur J Endocrinol, 2014, accepted)
is 20 kDa-GH) are responsible for the (patho-) physio-
logical condition, Tsushima et al. 36 reported constant
ratios of 20 kDa- and 22 kDa GH, regardless of normal
or short stature. Also, it was proposed37 that, minor
isoforms (neither 22 kDa, nor 20 kDa) might account
for the effects observed by Boguszewski et al.
An MS-based study may be expected to reduce am-
biguity by providing better analytical resolution, as
enabled by mass-selective differentiation of isoform-
specific peptides.
Defining cut-off levels
The determination of diagnostic decision levels gener-
ally involves lengthy and elaborate clinical studies. It
is particularly important therefore, to have the measur-
and well-defined at the outset. As it has been pointed
out, present knowledge about what is the optimal mea-
surand in GH-related diseases (sum of GH-forms, in-
dividual isoform(s), bound/free ratio, other?) may be
advanced by MS-methods of measurement.
A major limitation associated with exclusive refer-
ence to LBA measurement in determination of cut-off
values it is that, the antibody may not be available any-
more at a later point, as well as the calibrator may be
replaced by another one, which changes will hamper ap-
plicability (reproducibility) then, of results.
MS, as opposed to this, has the potential of estab-
lishing sustainable reproducibility, independent of what
laboratory or MS-platform being used. An example for
MS-based cut-off determination for diagnosis of GH-
deficiency is given in Figure 7. In spite of the limited
size of the data set (n = 30 patients), it appears that
both, T6 and T12, equally discriminate between healthy
and GH-deficient children. The ratio between the cut-
offs obtained for T6 and T12, 5.9 and 6.8 ng/mL, is
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Figure 8: Changes in serum concentrations of 20 kDa-GH
(•) and 22 kDa-GH (◦) and the ratio of 20 kDa/22 kDa (bar)
after administration of 22 kDa-GH. The arrows represent the
time of administration. (Reproduced with permission from
Momomura et al.,39 Endocr J, 2000, 47, 97–101 c©2000 The
Japan Endocrine Society)
roughly reflecting the expected fraction of 22 kDa GH
within total GH (here: 87%). In the original study,19
the purpose of including MS-measurement was estab-
lishing a metrological link to the LBA-based cut-off val-
ues.
Supporting doping control
Present detection strategies for GH-doping in sports
have been reviewed by Baumann.38 The particular po-
tential of MS-based proteomics methods for detection
of protein doping has been highlighted by Kay and
Creaser,29 and a review, summarizing recent develop-
ments in the area, has been published by van den Broek
et al. 30 Insufficient sensitivity uniformly was discussed
to be the main obstacle to application of MS. However,
the examples and data provided in the previous sections
indicate that, the sensitivity needed may be attainable
if applying the latest generation of MS-instruments in
combination with optimized sample preparation.
In growth hormone doping, recombinant 22 kDa-GH,
putatively, is the common form of administration. The
intake will increase the serum GH-level for about 20 h
(window of opportunity in doping-control). Neverthe-
less, definition of an (absolute) cut-off concentration, as
a way to unambiguously detect such event, is not vi-
able: Fluctuations from as little as 0.01 ng/mL up to
about 20-30 ng/mL (or even more) are not uncommon,
as resulting from just normal biorhythm, with a peak-
to-peak interval of 2–3 h. In addition, elevated GH-
levels may also occur as response to physical exercise,
stress or fasting.38
Therefore, ’isoform-differential’ tests have been devel-
oped which do not depend on absolute concentrations
of the hormone. Instead, the disturbance of the nat-
ural spectrum of isoforms, which results from exoge-
nous administration of the 22 kDa-GH, is used as an
indicator. Based on this notion, e.g. Wu et al. 40 and
Bidlingmaier et al. 41 developed methods using a combi-
nation of antibodies recognizing different GH-fractions,
each: One type of antibodies specifically measures only
22 kDa-GH (’rec GH’), while the other one recognizes
all forms secreted by the pituitary (’pit GH’). Ele-
vated rec/pit-ratios are taken indicative of doping with
22 kDa-GH. Momomura et al.,39 on the other hand,
proposed a combination of antibodies, which both are
isoform-specific, targeting the 22 kDa- and the 20 kDa-
form, respectively. The principle is illustrated in Fig-
ure 8.
Exploration of the potential of MS in this area is
suggesting itself. MS-based acquisition of isoform-
ratios could be expected to either directly improve dis-
crimination between both classes of samples (doped
or not), or, at least, be used to back-up findings by
LBAs. The epitope-recognition principles of the exist-
ing tests can be translated into signature peptides for
MS-measurement in a straightforward way: T6/T12-
ratios, e.g. may be deemed to map a quantity corre-
sponding to the rec/pit assay, as T6 selectively mea-
sures 22 kDa-GH, while T12 represents ’total GH’ (see
Figure 3). Replacing T12 by T4 (confined to the sub-
stretch exclusively present on 20 kDa-GH), measuring
T6/T4-ratios thus, would constitute an MS-analogy to
the method of Momomura et al. 39
Future perspective
The previous sections support the conclusion that,
MS provides an effective alternative to traditional
(antibody-based) ligand-binding assays in GH-
measurement. Advantages of MS result from (i) high
analytical selectivity enabled by mass-recognition
instead of epitopes, (ii) flexibility and precision in
targeting particular (iso-) forms by using signature
peptides and (iii) ease of integration of isotope labeled
internal standards into the protocol. By virtue of
these features, many of the problems encountered
with ligand binding assays either do not occur at all
with MS-methods, or may be overcome in a simple
way. This does not just apply to interferences with
binding- or other proteins, and commutability issues
resulting therefrom, but also to imprecisions in defini-
tion/recognition of the targeted epitope or GH-form,
in a more general sense.
The technology has matured to the extent as being
available for either direct measurement of patient sam-
ples (thus replacing ligand-binding assays), or value-
assignment to serum-based control- and reference ma-
terials (supporting calibration and proficiency testing
of antibody-based, ligand-binding assays). Harmoniz-
ing efforts for present commercial tests, no doubt, can
capitalize on comparison with MS-results. Equally im-
portant it is, however, that the option of highly selective
(iso-) form specific GH-quantification by MS has much
promise as analytical tool to support further investiga-
tion into the putatively different biological functions of
these forms, and if different, which particular functions
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these are.
The advantages associated with MS- based measure-
ment eventually might outweigh the main assets of
ligand-binding assays, as low costs and ease of use in
routine. The more so, if considering that, results are
scarcely needed within a few hours in diagnosis of GH-
related disorders. The time, MS analysis takes, and
higher costs per analysis, in practice might pay off in
terms of more accurate classification of patients, and
of costs avoided, which would result from inappropriate
treatment. Therefore, the authors speculate, MS even
might supersede the antibody-based assays in clinical
practice, within a few years’ time.
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